» Articles » PMID: 27588200

Conditions for the Generation of Cytotoxic CD4(+) Th Cells That Enhance CD8(+) CTL-mediated Tumor Regression

Overview
Date 2016 Sep 3
PMID 27588200
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Adoptive cell therapies (ACTs) using tumor-reactive T cells have shown clinical benefit and potential for cancer treatment. While the majority of the current ACT are focused on using CD8(+) cytotoxic T lymphocytes (CTL), others have shown that the presence of tumor-reactive CD4(+) T helper (Th) cells can greatly enhance the anti-tumor activity of CD8(+) CTL. However, difficulties in obtaining adequate numbers of CD4(+) Th cells through in vitro expansion can limit the application of CD4 Th cells in ACT. This study aims to optimize the culture conditions for mouse CD4 T cells to provide basic information for animal studies of ACT using CD4 T cells. Taking advantage of the antigen-specificity of CD4(+) Th cells from OT-II transgenic mice, we examined different methodologies for generating antigen-specific CD4(+) Th1 cells in vitro. We found that cells grown in complete advanced-DMEM/F12 medium supplemented with low-dose IL-2 and IL-7 induced substantial cell expansion. These Th cells were Th1-like, as they expressed multiple Th1-cytokines and exhibited antigen-specific cytotoxicity. In addition co-transfer of these CD4(+) Th1-like cells with CD8(+) CTL significantly enhanced tumor regression, leading to complete cure in 80% of mice bearing established B16-OVA. These observations indicate that the CD4(+) Th1-like cells generated using the method we optimized are functionally active to eliminate their target cells, and can also assist CD8(+) CTL to enhance tumor regression. The findings of this study provide valuable data for further research into in vitro expansion of CD4(+) Th1-like cells, with potential applications to cancer treatment involving ACT.

Citing Articles

TP53TG1/STAT axis is involved in the development of colon cancer through affecting PD-L1 expression and immune escape mechanism of tumor cells.

Ji W, Wang W, Wei Y Am J Cancer Res. 2023; 13(11):5218-5235.

PMID: 38058799 PMC: 10695788.


Association of clinical outcomes and the predictive value of T lymphocyte subsets within colorectal cancer patients.

Yuan C, Huang J, Li H, Zhai R, Zhai J, Fang X Front Surg. 2023; 10:1102545.

PMID: 37206348 PMC: 10188938. DOI: 10.3389/fsurg.2023.1102545.


Modulation of TCR Signaling by Tyrosine Phosphatases: From Autoimmunity to Immunotherapy.

Castro-Sanchez P, Teagle A, Prade S, Zamoyska R Front Cell Dev Biol. 2021; 8:608747.

PMID: 33425916 PMC: 7793860. DOI: 10.3389/fcell.2020.608747.


Relationship between infiltrating lymphocytes in cancerous ascites and dysfunction of Cajal mesenchymal cells in the small intestine.

Wang X, Li J, Liu D, Zhang L, Zhao B, Tang J Int J Clin Exp Pathol. 2020; 11(4):2201-2213.

PMID: 31938332 PMC: 6958188.


Assay and Isolation of Single Proliferating CD4+ Lymphocytes Using an Automated Microraft Array Platform.

LaBelle C, Zhang R, Armistead P, Allbritton N IEEE Trans Biomed Eng. 2019; 67(8):2166-2175.

PMID: 31794384 PMC: 7247929. DOI: 10.1109/TBME.2019.2956081.


References
1.
Trinchieri G . Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995; 13:251-76. DOI: 10.1146/annurev.iy.13.040195.001343. View

2.
Xu L, Wang C, Wen Z, Zhou Y, Liu Z, Liang Y . CpG oligodeoxynucleotides enhance the efficacy of adoptive cell transfer using tumor infiltrating lymphocytes by modifying the Th1 polarization and local infiltration of Th17 cells. Clin Dev Immunol. 2010; 2010:410893. PMC: 2963116. DOI: 10.1155/2010/410893. View

3.
Tan J, Ernst B, Kieper W, Leroy E, Sprent J, Surh C . Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med. 2002; 195(12):1523-32. PMC: 2193564. DOI: 10.1084/jem.20020066. View

4.
Kennedy R, Celis E . T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol. 2006; 177(5):2862-72. PMC: 1594817. DOI: 10.4049/jimmunol.177.5.2862. View

5.
Quezada S, Simpson T, Peggs K, Merghoub T, Vider J, Fan X . Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010; 207(3):637-50. PMC: 2839156. DOI: 10.1084/jem.20091918. View